P-011 Hematopoietic reconstitution and infections after anti-BCMA CAR T-cell therapy in relapsed/ refractory multiple myeloma are associated with pre-CAR-T bridging therapies
Jan Frenking(German Cancer Research Center), Marc S. Raab(Unknown), Marina Hajiyianni(Heidelberg University), Lilli Sester, Christian Michel(Philipps University of Marburg), Niels Weinhold(German Cancer Research Center), Joseph Kauer, Hartmut Goldschmidt(Heidelberg University), Michael Henry Schmitt(Heidelberg University), Sandra Sauer(Heidelberg University), Peter Dreger(Heidelberg University), Elias Mai(Heidelberg University), Lukas John(University of Hohenheim), Anita Schmitt(Heidelberg University), Carsten Müller‐Tidow(Heidelberg University)
Cited by 0
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493